IGI Laboratories, Inc. (NYSE Amex: IG). On May 25, 2010, IGI received notice from the NYSE Amex staff indicating that the Company is below certain of the Exchange's continued listing standards due to losses in five of its most recent fiscal years with equity below $6 million, as set forth in Section 1003(a) (iii) of the NYSE Amex Company Guide.
The Company was afforded the opportunity to submit a plan of compliance to the exchange and on June 24, 2010 presented its plan to the Exchange. On August 6, 2010 the Exchange notified IGI that it accepted the Company's plan of compliance and granted IGI an extension until February 25, 2011 to regain compliance with the continued listing standards. IGI will be subject to periodic review by Exchange Staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in IGI being delisted from the NYSE AMEX LLC.